

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

TNF-R1 (C25C1) Rabbit mAb

RRID:AB_2241018

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3736, RRID:AB_2241018

Antibody Information

URL: http://antibodyregistry.org/AB_2241018

Proper Citation: Cell Signaling Technology Cat# 3736, RRID:AB_2241018

Target Antigen: TNF-R1 (C25C1) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP

Antibody Name: TNF-R1 (C25C1) Rabbit mAb

Description: This monoclonal targets TNF-R1 (C25C1) Rabbit mAb

Target Organism: h, human

Antibody ID: AB_2241018

Vendor: Cell Signaling Technology

Catalog Number: 3736

Record Creation Time: 20231110T075448+0000

Record Last Update: 20260901T062119+0000

Ratings and Alerts

No rating or validation information has been found for TNF-R1 (C25C1) Rabbit mAb.

No alerts have been found for TNF-R1 (C25C1) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Ngalula S, et al. (2025) TNF- α -Driven Changes in Polarized EGF Receptor Trafficking Facilitate Phosphatidylinositol 3-Kinase/Protein Kinase B Signaling From the Apical Surface of MDCK Epithelial Cells. *Traffic* (Copenhagen, Denmark), 26(4-6), e70005.

Wu M, et al. (2025) Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors. *Immunity*, 58(11), 2864.

Lampson BL, et al. (2024) Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF- κ B. *Cell*, 187(9), 2209.

Imai T, et al. (2024) The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation. *Immunity*, 57(7), 1497.

Elliott PR, et al. (2021) Regulation of CYLD activity and specificity by phosphorylation and ubiquitin-binding CAP-Gly domains. *Cell reports*, 37(1), 109777.

Bowling EA, et al. (2021) Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. *Cell*, 184(2), 384.

Solà-Riera C, et al. (2019) Hantavirus Inhibits TRAIL-Mediated Killing of Infected Cells by Downregulating Death Receptor 5. *Cell reports*, 28(8), 2124.